OncoMatch/Clinical Trials/NCT03093909
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Is NCT03093909 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Gemcitabine for malignant neoplasm of bone and articular cartilage.
Treatment: Gemcitabine — Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to find the highest tolerable dose of gemcitabine that can be given by inhalation (breathing it as a mist) to patients with solid tumors that have spread to the lungs from other parts of the body. The safety and side effects of this drug will also be studied. This is an investigational study. Gemcitabine is FDA approved and commercially available for the treatment of pancreatic and lung cancer, and other solid tumors. Its administration by inhalation is investigational. The study doctor can explain how the study drug is designed to work. Up to 44 participants will be enrolled in this study. All will take part at MD Anderson.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Melanoma
Disease stage
Metastatic disease required
Performance status
ECOG OR LANSKY 0–2
ECOG <= 2 for patients >= 16 years old or Lansky play >= 60% for patients <=15 years old
Prior therapy
Cannot have received: radiotherapy
Exception: within 2 weeks
No radiotherapy within 2 weeks
Lab requirements
Blood counts
ANC >= 1,000/mm3, platelet count >= 100,000/mm3 (transfusion independent), hemoglobin >= 8.0g/dl (may receive RBC transfusions)
Kidney function
creatinine <= 2 x ULN
Liver function
bilirubin and AST <= 5x ULN
Adequate organ function as defined by: peripheral absolute neutrophil count (ANC) >= 1,000/mm3, platelet count >= 100,000/mm3 (transfusion independent defined as not receiving platelet transfusions within a 7 day period prior to enrollment), hemoglobin >= 8.0g/dl (may receive RBC transfusions), renal-creatinine <= 2 x ULN; hepatic- bilirubin and AST <= 5x ULN; pulmonary: FVC >=50% predicted, Oxyhemoglobin saturation at rest >=95% (off supplemental oxygen).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify